Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma

Dong, Baowei; Zhang, J; Liang, Ping; Yu, Xiaoling; Su, Li Ming; Yu, Dejiang; Ji, Xiaolong; Guo, Yu

doi:10.1080/0265673021000017154

Cited by 73 publications

(53 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on our clinical experience accumulated over 12 years, we determined that microwave ablation for secondary splenomegaly and hypersplenism is safe and effective. Previous studies have shown that immune function was enhanced in HCC patients receiving microwave ablation therapy for tumours [23][24][25][26][27]. However, changes in immune status of patients receiving microwave ablation for the spleen remained unknown.…”

Section: Discussionmentioning

confidence: 99%

“…PMCT can produce a controlled volume of necrosis and can be used for haemostasis, so it might be adopted to decrease the splenic parenchyma in treating hypersplenism. It was reported that in patients receiving microwave ablation therapy for HCC, the immune function towards tumour was enhanced [23][24][25][26][27]. However, no studies have been conducted yet studying the effects of microwave ablation therapy for splenomegaly and hypersplenism on parameters associated with the patient's immune system.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in peripheral lymphocyte subsets in patients after partial microwave ablation of the spleen for secondary splenomegaly and hypersplenism: A preliminary study

Duan

Gao

et al. 2007

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Changes in peripheral lymphocyte subsets in patients after partial microwave ablation of the spleen for secondary splenomegaly and hypersplenism: A preliminary study

Duan

Gao

et al. 2007

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

show abstract

“…Third, as the tumor recurrence rate is high even after complete tumor ablation, adjuvant therapies may be employed after MWA to inhibit tumor relapse, and further studies are warranted to observe the effectiveness of adjuvant therapies. Improvement of the patient’s immune status is beneficial to long-term survival [59]. Immunologic therapy may be adopted in the future to up-regulate the systemic immune response towards tumor.…”

Section: Clinical Applicationmentioning

confidence: 99%

Microwave Ablation of Hepatocellular Carcinoma

2007

View full text Add to dashboard Cite

Objective: This article reviews the basic principles, equipment, current therapeutic status and future trends of microwave ablation (MWA) in the treatment of hepatocellular carcinoma (HCC). Methods: All articles published in English on MWA or MWA as a treatment for HCC were identified with a PubMed search from the 1990s through June 2007. Papers were reviewed on the technical advances of MWA equipment and the clinical applications of MWA including indications, techniques, therapeutic outcomes, complications and combination therapies. Results: MWA has several advantages, including high thermal efficiency, higher capability of coagulating blood vessels, faster ablation time, and an improved convention profile. MWA can induce large ablation volumes and yield good local tumor control, especially for small HCC. Larger HCC can also be completely ablated by using more effective antenna or simultaneous application of multiple antennae. Long-term survival comparable to that of surgery was obtained for tumors measuring 4 cm or less. Associated complications appear to be low. Conclusions: MWA is a promising minimally invasive technique for the treatment of HCC. Future advances are warranted to improve the therapeutic efficacy.

show abstract

“…The results of our previous research demonstrated that PMWA stimulated local immune response, however lasting only a short time, suggesting that immunotherapy after ablation therapy should be performed. 16 Tumor load is temporarily reduced to a minimum after ablation therapy of HCC, which represents the best opportunity to perform immunotherapy. Therefore, we planned two courses of adoptive immunotherapy with multiple immunocytes and multiple reinfusion routes to be undertaken within 11 days post-PMWA, and one additional course to be started 100 days after PMWA.…”

Section: Discussionmentioning

confidence: 99%

Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma

Zhou

Liang²,

Dong³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Percutaneous ablation therapy has been widely accepted as one of the radical treatment methods for small hepatocellular carcinoma (HCC) and the 5-year survival rate is similar to that obtained by resection. 1 The search for new and effective methods to prolong the overall survival and disease-free survival time requires further advances. HCC is a potential target for immunotherapy, as evidenced by an active recruitment of tumor-infiltrating lymphocytes (TIL) that display antitumor cytolytic activity in the presence of interleukin (IL) 2 in ex vivo studies.2 However, TIL in HCC are of dysfunction, few in quantity and do not kill tumor cells, which suggests that immunosuppressive mechanisms prevent T cells from maturing into effective antitumor effectors. The activation of tumor-specific cytotoxic T lymphocytes (CTL) requires three synergistic signals: the presentation of tumor antigen by antigen-presenting cells (APC) to specific T-helper cells; the interaction between costimulatory factors (such as B7.1 and CD28 ligand); Background and Aims: To observe safety and influence on viral load and peripheral T-lymphocyte subsets of combination therapy with percutaneous microwave ablation (PMWa) and adoptive immunotherapy in hepatocellular carcinoma (HCC) with hepatitis B.Results: no adverse effects of grade iii/iV were observed. Viral load was decreased in 57.14% (four of seven) of patients and was undetectable in two (28.6%) patients without antiviral therapy. The percentage of Cd4 + Cd25 high regulatory T lymphocytes decreased significantly and the percentage of Cd8 + Cd28 -effector cells increased significantly 1 month after therapy. However, 6 months after therapy, there was no significant difference.Methods: Ten HCC (d ≤5 cm, fewer than three tumors) patients were treated with radical PMWa and three courses of immunotherapy, which were started with PMWa, 2 weeks post-PMWa and 3 months after PMWa. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed dCs and effector cells. immature dCs, cytokineinduced killer cells (CiK) and cytotoxic T lymphocytes (CTL) were injected into the marginal area of ablated tumors under contrast-enhanced sonographic guidance. under sonographic guidance, tumor lysate-pulsed dC was injected into groin lymph nodes, while dC-CiK and CTL were injected into the abdominal cavity. CiK was infused intravenously.Conclusion: adoptive immunotherapy prescribed soon after PMWa for HCC patients was safe and ameliorated the percentage of peripheral lymphocytes.

show abstract

Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma

Abstract: For inoperable HCC patients, PMCT is one of the treatment choices shown to be effective. Apart from its tissue coagulation effect, an increased systemic immune response directed against the tumour may also play an important role in improved survival.

Cited by 73 publications

References 12 publications

Changes in peripheral lymphocyte subsets in patients after partial microwave ablation of the spleen for secondary splenomegaly and hypersplenism: A preliminary study

Changes in peripheral lymphocyte subsets in patients after partial microwave ablation of the spleen for secondary splenomegaly and hypersplenism: A preliminary study

Microwave Ablation of Hepatocellular Carcinoma

Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma

Contact Info

Product

Resources

About